|
KMID : 1039120220110010116
|
|
Clinical and Experimental Vaccine Research
2022 Volume.11 No. 1 p.116 ~ p.120
|
|
|
Assessment on anti-SARS-CoV-2 receptor-binding domain antibodies among CoronaVac-vaccinated Indonesian adults
|
|
Jo Juandy
Sanjaya Astia
Pinontoan Reinhard
Aruan Maroloan
Wahyuni Rury Mega
Viktaria Venansi
|
|
|
Abstract
|
|
|
|
The immunogenicity of CoronaVac among Indonesian adults at the academic premises was investigated. Two doses of CoronaVac vaccine induced a complete seroconversion on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naive adults with titers of anti-SARS-CoV-2 receptor-binding domain (RBD) antibodies ranging from 9.1 to 151.9 U/mL. The median value was lower than the one observed in recovered adults with mild coronavirus disease 2019 (38.7 vs. 114.5 U/mL). Nonetheless, 93.6% of the vaccinated adults, in contrast to 76.5% of the recovered adults, displayed inhibition rates above the cut-off to block RBD-angiotensin-converting enzyme 2 binding. This suggests that two doses of CoronaVac were immunogenic and likely to be protective among Indonesian adults.
|
|
|
KEYWORD
|
|
|
COVID-19, CoronaVac vaccine, Anti-SARS-CoV-2 RBD antibody
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|